101. Systematic replacement of amides by 1,4-disubstituted[1,2,3]triazoles in Leu-enkephalin and the impact on the delta opioid receptor activity
- Author
-
Pierre-Julien Albert, Louis Gendron, Arnaud Proteau-Gagné, Kristina Rochon, Yves L. Dory, Brigitte Guérin, and Mélissa Roy
- Subjects
1,2,3-Triazole ,Peptidomimetic ,Stereochemistry ,Clinical Biochemistry ,Triazole ,Pharmaceutical Science ,Peptide ,Binding, Competitive ,Biochemistry ,Article ,Inhibitory Concentration 50 ,chemistry.chemical_compound ,Receptors, Opioid, delta ,Amide ,Drug Discovery ,Peptide synthesis ,Molecular Biology ,chemistry.chemical_classification ,Molecular Structure ,Organic Chemistry ,Hydrogen Bonding ,Biological activity ,Triazoles ,Leu-enkephalin ,Amides ,chemistry ,Molecular Medicine ,Peptidomimetics ,Enkephalin, Leucine - Abstract
Using Cu(I)-catalyzed azide-alkyne cycloaddition in a mixed classical organic phase and solid phase peptide synthesis approach, we synthesized four analogs of Leu-enkephalin to systematically replace amides by 1,4-disubstituted[1,2,3]triazoles. The peptidomimetics obtained were characterized by competitive binding, contractility assays and ERK1/2 phosphorylation. The present study reveals that the analog bearing a triazole between Phe and Leu retains some potency, more than all the others, suggesting that the hydrogen bond acceptor capacity of the last amide of Leu-enkephalin is essential for the biological activity of the peptide.
- Published
- 2013
- Full Text
- View/download PDF